Health-related quality of life of exposed versus non-exposed androgen deprivation therapy patients with prostate cancer: a cross-sectional study

  • Yu-Ting Huang
  • Ching‐Chia Li
  • Yii-Her Chou
  • Hung‐Lung Ke
  • Chung-Yu ChenEmail author
Research Article


Background The survival rate of prostate cancer is relatively higher than other cancers, therefore, the health-related quality of life (HRQoL) becomes a critical issue for the patients. There are limited quality of life data evaluating the difference between androgen deprivation therapy and non-androgen deprivation therapy. Objective To evaluate the HRQoL among prostate cancer patients with androgen deprivation therapy and non-androgen deprivation therapy in an Asian population. Setting The study was conducted at the urology outpatient department in a medical center and a regional hospital in southern Taiwan. Methods We collected the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire-Prostate (QLQ-PR25) among prostate cancer patients with and without androgen deprivation therapy from December 2017 to June 2018. The androgen deprivation therapy subjects in this study were using goserelin, leuprolide, degarelix, bicalutamide, enzalutamide, cyproterone, and abiraterone. The non-androgen deprivation therapy subjects were only receiving radiation therapy or radical prostatectomy. To investigate the determinants of HRQoL between androgen deprivation therapy and non-androgen deprivation therapy, multiple linear regression was used. Main outcomes measures The scores of EORTC QLQ-C30 and QLQ-PR25. Results In total, 182 subjects participated in the study of which 116 (63.74%) were in androgen deprivation therapy user group with a mean age (± SD, standard deviation) of 75.94 years (± 8.31), and 66 (36.26%) subjects were in non-androgen deprivation therapy user group with a mean age of 70.6 years (± 7.1). androgen deprivation therapy users’ quality of life was significantly lower than non-androgen deprivation therapy users (72.1 ± 19.3 vs. 77.8 ± 16.6, p = 0.0493). Conclusions The quality of life of patients with all-stages prostate cancer differs significantly between androgen deprivation therapy users and non-androgen deprivation therapy users. The HRQoL for androgen deprivation therapy users is worse than for the non-androgen deprivation therapy users. Additionally, the symptoms are the key determinants of the quality of life.


Androgen deprivation therapy Prostate cancer Quality of life Radiation therapy Taiwan 



We would like to thank the Center for Drug Evaluation and Ministry of Health and Welfare, Taiwan for supporting the program, and all the physicians who participated in this study. We also want to thank Dr. Tsu-Ming Chien for assistance in the writing of the study protocol.


This work was supported by a grant from the Center for Drug Evaluation and Ministry of Health and Welfare, Taiwan for supporting the program (RC1051116 and MOHW107-TDU-M-212-134005).

Conflicts of interest

The authors have no conflict of interest.

Supplementary material

11096_2019_854_MOESM1_ESM.docx (33 kb)
Supplementary material 1 (DOCX 33 kb)


  1. 1.
    Ministry of Health and Welfare. Death statistics annual report. 2017. Accessed 23 July 2018.
  2. 2.
    Ministry of Health and Welfare. 2015 Taiwan Cancer Registry. Accessed 29 Jan 2015.
  3. 3.
    National Cancer Institute. Cancer stat facts: prostate cancer. 2016; (2018). Accessed 12 Jan 2018.
  4. 4.
    Namiki S, Arai Y. Health-related quality of life in men with localized prostate cancer. Int J Urol. 2010;17(2):125–38.CrossRefGoogle Scholar
  5. 5.
    Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP, et al. Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA. 2017;317(11):1141–50.CrossRefGoogle Scholar
  6. 6.
    Namiki S, Kwan L, Kagawa-Singer M, Tochigi T, Ioritani N, Terai A, et al. Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. Prostate Cancer Prostatic Dis. 2008;11(3):298–302.CrossRefGoogle Scholar
  7. 7.
    Cella DF. Measuring quality of life in palliative care. Semin Oncol. 1995;22(2 Suppl 3):73–81.Google Scholar
  8. 8.
    Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013;2(4):445–60.CrossRefGoogle Scholar
  9. 9.
    Shields AL, Hao Y, Krohe M, Yaworsky A, Mazar I, Foley C, et al. Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges. Am Health Drug Benefits. 2016;9(4):188–97.Google Scholar
  10. 10.
    Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol. 2019;19(1):19.CrossRefGoogle Scholar
  11. 11.
    Adamowicz K. Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials. Qual Life Res. 2017;26(4):813–22.CrossRefGoogle Scholar
  12. 12.
    Osoba D. Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol. 2011;3(2):57–71.CrossRefGoogle Scholar
  13. 13.
    Murasawa H, Sugiyama T, Matsuoka Y, Okabe T, Hino A, Tanaka N, et al. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. UQual Life Res. 2019. Scholar
  14. 14.
    Lopez-Calderero I, Lopez-Fando L, Rios-Gonzalez E, Maisonobe P, Hernández-Yuste E, Sarmiento-Jordán M, et al. Impact of locally advanced or metastatic prostate cancer on the quality of life. Actas Urol. Esp. 2017;41(6):368–75.CrossRefGoogle Scholar
  15. 15.
    Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. The New England journal of medicine. 2016;375(15):1425–37.CrossRefGoogle Scholar
  16. 16.
    Hashine K, Azuma K, Koizumi T, Sumiyoshi Y. Health-related quality of life and treatment outcomes for men with prostate cancer treated by combined external-beam radiotherapy and hormone therapy. Int J Clin Oncol. 2005;10(1):45–50.CrossRefGoogle Scholar
  17. 17.
    Chie W-C, Yu C-C, Yu H-J. Reliability and validity of the Taiwan Chinese Version of the EORTC QLQ-PR25 in assessing quality of life of prostate cancer patients. Urol Sci. 2010;21(3):118–25.CrossRefGoogle Scholar
  18. 18.
    Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual (3rd edition). European Organisation for Research and Treatment of Cancer; 2001.Google Scholar
  19. 19.
    Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, et al. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014;32(13):1324–30.CrossRefGoogle Scholar
  20. 20.
    Health Promotion Administration Ministry of Health and Welfare Taiwan. Cancer registry annual report, 2015 Taiwan. Accessed 27 Dec 2017.
  21. 21.
    National Health Research Institutes. Guideline for clinical diagnosis and treatment of prostate cancer. 2010; 2010:120.Google Scholar
  22. 22.
    National Comprehensive Cancer Network. National Cancer Institute Cancer Stat Facts: Prostate Cancer (Version 2.2017). 2017; Accessed 8 Jan 2018.
  23. 23.
    Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753–60.CrossRefGoogle Scholar
  24. 24.
    Bergius S, Torvinen S, Muhonen T, Roine RP, Sintonen H, Taari K. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment. Scand J Urol. 2017;51(1):13–9.CrossRefGoogle Scholar
  25. 25.
    Mendez LC, Raman S, Wan BA, da Silva JLP, Moraes FY, Lima KMLB, et al. Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort. Ann Palliat Med. 2017;6(Suppl 1):S65–s70.CrossRefGoogle Scholar
  26. 26.
    Drummond FJ, Kinnear H, O’Leary E, Donnelly, Gavin A, Sharp L. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv. 2015;9(2):361–72.CrossRefGoogle Scholar
  27. 27.
    Bach P, Doring T, Gesenberg A, Mohring C, Goepel M. Quality of life of patients after retropubic prostatectomy—pre- and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25. Health Qual Life Outcomes. 2011;9:93.CrossRefGoogle Scholar
  28. 28.
    Adam S, Feller A, Rohrmann S, Arndt V. Health-related quality of life among long-term (>/=5 years) prostate cancer survivors by primary intervention: a systematic review. Health Qual Life Outcomes. 2018;16(1):22.CrossRefGoogle Scholar
  29. 29.
    Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017;18(9):1192–201.CrossRefGoogle Scholar
  30. 30.
    Adam S, Feller A, Rohrmann S, Arndt V. Health-related quality of life among long-term (>/=5 years) prostate cancer survivors by primary intervention: a systematic review. Health Qual Life Outcomes. 2018;16(1):22.CrossRefGoogle Scholar
  31. 31.
    Lehto US, Tenhola H, Taari K, Aromaa A. Patients’ perceptions of the negative effects following different prostate cancer treatments and the impact on psychological well-being: a nationwide survey. Br J Cancer. 2017;116(7):864–73.CrossRefGoogle Scholar
  32. 32.
    Hung HY, Wu LM, Chen KP. Determinants of quality of life in lung cancer patients. J Nurs Scholarsh. 2018;50(3):257–64.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Master Program in Clinical Pharmacy, School of PharmacyKaohsiung Medical UniversityKaohsiungTaiwan, ROC
  2. 2.Department of UrologyKaohsiung Medical University HospitalKaohsiungTaiwan, ROC
  3. 3.Department of Urology, School of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan, ROC
  4. 4.Graduate Institute of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan, ROC
  5. 5.Department of PharmacyKaohsiung Medical University HospitalKaohsiungTaiwan, ROC
  6. 6.Department of Medical ResearchKaohsiung Medical University HospitalKaohsiungTaiwan, ROC

Personalised recommendations